Mycobacterium tuberculosis antigen containing-exosomes reinforce BCG vaccine efficacy by augmenting long term protection and memory response against experimental tuberculosis in BALB-C mice.

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb.) , inflicts one third of the humanity. Despite the availability of effective drug regimens, complete eradication of M.tb. remains challenging due to prolong treatment duration. Additionally, MDR-TB and co-infection HIV further exacerbate disease severity. The Bacille Calmette–Guérin (BCG) has shown inconsistent efficacy due to absence of Th-1-antigens. Hence, there is a critical need for either a novel vaccine candidate or an efficient booster to enhance BCG’s prophylactic efficacy.In this study, in-house prepared M.tb. -infected alveolar macrophage-derived exosomes (Rv-Exo) and ESAT-6-containing exosomes (ESAT-6 Exo) were characterized based on size, purity, and pathogen-associated molecular patterns (PAMPs) and their epitope mapping was also performed. These M.tb. protein-containing exosomes (MPE) were utilized for immunization, either alone or as a booster to BCG, and evaluated in BALB/c mice against experimental M.tb. challenge.Our results demonstrate the ESAT-6 Exo and Rv-Exo, either alone or as a BCG booster, enhanced Th1-biased immune responses by activating CD4⁺ and CD8⁺ T cells, increasing memory T-cell populations, and significantly reducing the M.tb. burden in the lungs, spleen, and lymph nodes of infected mice. There finding highlights the potential of MPE as a promising strategy against TB specially in BCG vaccinated population.

Article activity feed